ERBB2 and breast carcinoma: Some studies suggested ERBB2 would impair effect of TAM in breast cancer.50, 51 Recently, a study indicated ERBB2 mutations are the most extensively mutated pathway in GBC and were associated with poor prognosis in individuals.52 New ERBB2 inhibitors development in GBC is carrying out and will help TAM to achieve a better efficacy.53 Various endocrine therapies would be indispensable for GBC treatment in the future.